StreetInsider.com News Articles

Form 6-K Biodexa Pharmaceuticals For: Oct 14

Wed, 14 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27184298.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183135.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183136.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183138.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183140.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183141.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183143.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183144.html

Form 424B3 Biodexa Pharmaceuticals

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183145.html

Biodexa hits 100-patient mark in Phase 3 FAP trial

Tue, 13 Oct 2026 08:30:13 -0400

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa for Familial Adenomatous Polyposis, known as the Serenta trial.

The trial is currently recruiting at 29 clinical sites across the U.S. and five European countries, with two additional sites in Canada expected to open soon. The trial targets a total enrollment of 168 subjects, randomized 2:1 between drug and placebo.

The Serenta protocol includes a pre-specified futility analysis after 25 Progression Free Survival events and a database lock after 75 PFS events. Chief Executive Officer Stephen Stamp said the futility analysis "could

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

Tue, 13 Oct 2026 08:30:00 -0400

October 13, 2026

Biodexa announces another Serenta milestone
with 100 patients enrolled in its registrational Phase 3 trial in FAP

Update on expected timing of pre-specified futility analysis and database lock

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. The trial, branded “Serenta” is recruiting at 29 clinical sites across the

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

Tue, 13 Oct 2026 08:30:00 -0400

October 13, 2026

Biodexa announces another Serenta milestone
with 100 patients enrolled in its registrational Phase 3 trial in FAP

Update on expected timing of pre-specified futility analysis and database lock

Form F-6 POS Biodexa Pharmaceuticals Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary

Thu, 08 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261008/27167174.html

Form 6-K Biodexa Pharmaceuticals For: Oct 08

Thu, 08 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261008/27166955.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 06 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261006/27156435.html

Form EFFECT Biodexa Pharmaceuticals

Thu, 01 Oct 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20261001/27131012.html

Form F-1 Biodexa Pharmaceuticals

Thu, 24 Sep 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27099743.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061782.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061783.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061784.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061785.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061786.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061787.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061788.html

Form 6-K Biodexa Pharmaceuticals For: Sep 15

Tue, 15 Sep 2026 08:27:00 -0400

si-local-file:///var/storage/secattach/20260915/27061643.html